What do systematic reviews say?

25 questions · 25 findings · 11 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 25 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

SUPPORTIVE THERAPY vs FAMILY THERAPY

Quality of life ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Supportive therapy for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Perazine vs OTHER ANTIPSYCHOTICS

Quality of life ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Perazine vs placebo

Quality of life ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs placebo

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sildenafil vs placebo

Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy

The review found no eligible studies for this question.

1 finding from 1 review

Management of sexual dysfunction due to antipsychotic drug therapy 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs RISPERIDONE

Quality of life (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Quality of life (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Continuation vs reduction of polypharmacy

Quality of life: clinically important change ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC

Quality of life (medium term: 12 months) · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

Pimozide for schizophrenia or related psychoses 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Benzodiazepines vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Benzodiazepines for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CHOLINERGIC DRUGS vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Cholinergic medication for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levetiracetam vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Buspirone vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FATTY ACID ‐ ETHYL‐EPA vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ginkgo biloba vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Melatonin vs placebo or no treatment

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

POLYPEPTIDE ‐ CERULETIDE vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

HYPNOSIS or RELAXATION vs TAU

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 35 (mean) years old patients with schizophrenia and tardive dyskinesia, acute extrapyramidal symptoms, and/or…

The review found no eligible studies for this question.

1 finding from 1 review

Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found